Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Mark J. Ratain

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Ratain, Mark

Item TypeName
Concept Clinical Trials as Topic
Academic Article Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Academic Article Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
Academic Article Development of target-based antineoplastic agents.
Academic Article Conflict-of-interest policies.
Academic Article Pharmacogenomics: road to anticancer therapeutics nirvana?
Academic Article Clinical trial designs for cytostatic agents.
Academic Article Pharmacokinetic variability of anticancer agents.
Academic Article Finding the right dose.
Academic Article Interpreting P values in pharmacogenetic studies: a call for process and perspective.
Academic Article The value meal: how to save $1,700 per month or more on lapatinib.
Academic Article Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Academic Article Biomarkers in early cancer drug development: limited utility.
Academic Article The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Academic Article Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Academic Article Vascular endothelial growth factor pathway.
Academic Article Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
Academic Article Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
Academic Article Recommended changes to oncology clinical trial design: revolution or evolution?
Academic Article The investigational drug steering committee.
Academic Article Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Academic Article Why RECIST works and why it should stay--reply to counterpoint.
Academic Article Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
Academic Article Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
Academic Article Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
Academic Article A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
Academic Article Pharmacogenetics and pharmacogenomics of anticancer agents.
Academic Article RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.
Academic Article Drug combinations: dangerous liaisons or great expectations?
Academic Article Measuring response in a post-RECIST world: from black and white to shades of grey.
Academic Article Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Academic Article Pharmacogenetic pathway analysis of irinotecan.
Academic Article Opportunities and challenges in the development of experimental drug combinations for cancer.
Academic Article Cancer pharmacogenomics: strategies and challenges.
Academic Article Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Academic Article Tumour heterogeneity in the clinic.
Academic Article Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Academic Article Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
Academic Article Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
Academic Article Burdensome Research Procedures in Trials: Why Less Is More.
Academic Article Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
Academic Article Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.

Search Criteria
  • Clinical Trials as Topic